Elicit: Clinical Outcomes of Adalimumab in Rheumatoid Arthritis

Clinical Outcomes of Adalimumab in Rheumatoid Arthritis

Clinical outcomes rheumatoid arthritis adalimumab

Adalimumab achieves sustained clinical effectiveness in rheumatoid arthritis

Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment. Combination therapy with methotrexate substantially outperforms monotherapy, achieving 80% ACR50 responses at 10 years versus 69% with adalimumab alone, and preventing radiographic progression more effectively. Earlier treatment initiation yields superior outcomes, with patients having disease duration ≤2 years achieving normal function at rates of 61% versus 40% for those with longer disease duration. Adalimumab remains effective following TNF antagonist failure, with 60% ACR20 responses in this population. Safety profiles show serious infection rates of 2.4-2.8 events per 100 patient-years and mortality rates below general population expectations, with no unexpected safety signals during exposures extending beyond 5 years.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

Clinical Effectiveness

Disease Activity and Response Rates

Clinical effectiveness varied by study duration and population characteristics. In short-term studies, ACR20 response rates ranged from 37% at 4 weeks to 88% at 24 weeks. At 12 weeks, ACR20 responses were achieved by 50.7-60% of patients, ACR50 by 27-33%, and ACR70 by 8-13%. Long-term studies demonstrated sustained or improved response rates. Among patients who persisted on adalimumab for at least one year in the Corrona registry, 67% achieved low disease activity or remission, maintained over 10 years.

Remission and Low Disease Activity

Remission rates varied by definition and study duration. Using DAS28 <2.6 criteria, remission was achieved by 12-15.3% of patients at 12 weeks, increasing to 25% by 24 weeks. Low disease activity was achieved by 28.9% at 12 weeks in the CanACT study, and at year 10 in the PREMIER extension, DAS28 low disease activity was achieved by 92.3%.

Functional Outcomes

Functional status improved across studies, primarily measured by HAQ-DI. In the PREMIER trial, significant improvements from baseline HAQ-DI scores were noted. Long-term functional benefits were sustained. In the DE020 10-year study, 42.4% of completers achieved HAQ-DI <0.5.

Radiographic Progression

Radiographic outcomes were assessed in long-term studies, with modified total Sharp score change significantly lower with adalimumab plus MTX compared to adalimumab or MTX monotherapy.

Safety Outcomes

Safety data were reported across varying durations of exposure from 12 weeks to over 5 years. Overall adverse event rates varied. Serious adverse events occurred at rates of 2.6-13.8 events per 100 patient-years. Serious infections were reported at rates of 2.4-2.8 events per 100 patient-years. Mortality was lower than expected.

Patient-Reported Outcomes and Quality of Life

Health-related quality of life measures showed consistent improvements, with significant benefits noted in physical component scores, pain assessments, and functional measures. Long-term data showed stable reductions in physical disability.

Factors Influencing Treatment Effectiveness

Earlier treatment initiation consistently predicted better outcomes. Combination therapy with methotrexate outperformed monotherapy. Prior biologic exposure influenced treatment responses, and effectiveness of adalimumab remained even after prior TNF antagonist failure.